Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
265 participants
INTERVENTIONAL
2004-04-30
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis
NCT02643212
Anticoagulation in Liver Fibrosis in Patients With Hepatitis C Virus Infection
NCT00180674
Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding
NCT01095185
A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment
NCT03713242
A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
NCT05917938
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
activated recombinant human factor VII
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Vienna, , Austria
Novo Nordisk Investigational Site
Olomouc, , Czechia
Novo Nordisk Investigational Site
Prague, , Czechia
Novo Nordisk Investigational Site
Prague, , Czechia
Novo Nordisk Investigational Site
Aarhus, , Denmark
Novo Nordisk Investigational Site
Helsinki, , Finland
Novo Nordisk Investigational Site
Angers, , France
Novo Nordisk Investigational Site
Caen, , France
Novo Nordisk Investigational Site
Clichy, , France
Novo Nordisk Investigational Site
Grenoble, , France
Novo Nordisk Investigational Site
Lille, , France
Novo Nordisk Investigational Site
Limoges, , France
Novo Nordisk Investigational Site
Marseille, , France
Novo Nordisk Investigational Site
Nantes, , France
Novo Nordisk Investigational Site
Nice, , France
Novo Nordisk Investigational Site
Paris, , France
Novo Nordisk Investigational Site
Paris, , France
Novo Nordisk Investigational Site
Toulouse, , France
Novo Nordisk Investigational Site
Villejuif, , France
Novo Nordisk Investigational Site
Berlin, , Germany
Novo Nordisk Investigational Site
Heidelberg, , Germany
Novo Nordisk Investigational Site
Leipzig, , Germany
Novo Nordisk Investigational Site
München, , Germany
Novo Nordisk Investigational Site
Münster, , Germany
Novo Nordisk Investigational Site
Ulm, , Germany
Novo Nordisk Investigational Site
Shatin, , Hong Kong
Novo Nordisk Investigational Site
Milan, , Italy
Novo Nordisk Investigational Site
Napoli, , Italy
Novo Nordisk Investigational Site
Palermo, , Italy
Novo Nordisk Investigational Site
Katowice, , Poland
Novo Nordisk Investigational Site
Krakow, , Poland
Novo Nordisk Investigational Site
Warsaw, , Poland
Novo Nordisk Investigational Site
Badalona, , Spain
Novo Nordisk Investigational Site
Barcelona, , Spain
Novo Nordisk Investigational Site
Barcelona, , Spain
Novo Nordisk Investigational Site
Barcelona, , Spain
Novo Nordisk Investigational Site
Córdoba, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Madrid, , Spain
Novo Nordisk Investigational Site
Majadahonda, , Spain
Novo Nordisk Investigational Site
Taipei, , Taiwan
Novo Nordisk Investigational Site
Leeds, , United Kingdom
Novo Nordisk Investigational Site
London, , United Kingdom
Novo Nordisk Investigational Site
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg. 2008 Jul;248(1):61-8. doi: 10.1097/SLA.0b013e318176c4ec.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F7LIVER-1533
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.